MRK - Merck & Co Inc Stock Price Quote - NYSE | Morningstar

Skip to Content

Is it the right time to buy or sell?

Find out with Morningstar Investor

Is it the right time to buy or sell?

Find out with Morningstar Investor

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Merck Is Poised for Steady Growth Led by Immuno-Oncology Drug Keytruda and Vaccine Gardasil

Sector Strategist Karen Andersen

Karen Andersen, CFA Sector Strategist

Business Strategy and Outlook

| Damien Conover, CFA | Jun 21, 2022

Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the Organon business in June 2021, the remaining portfolio at Merck holds a higher percentage of drugs with strong patent protection. On the pipeline front, after several years of only moderate research and development productivity, Merck's drug development strategy is yielding important new drugs.

Unlock Our Full Analysis With Morningstar Investor

Merck & Co Inc's Company Profile

Business Description

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Contact

2000 Galloping Hill Road
Kenilworth, NJ, 07033

T +1 908 740-4000

investor_relations@merck.com

Sector Healthcare

Industry Drug Manufacturers - General

Most Recent Earnings Mar 31, 2022

Fiscal Year End Dec 31, 2022

Stock Type Classic Growth

Employees 68,000

Merck & Co Inc's Related News

Markets Brief: How High Can Mortgage Rates Go?

Existing home sales figures from May are on deck. Energy stocks lose juice, while Chinese ADRs continue to rally.

21 Best Healthcare Companies to Invest In

These companies largely earn their competitive advantage from intangible assets and their stocks are great choices for an investor’s watchlist.

Benjamin Slupecki

Stock Strategist Industry Reports

21 Best Healthcare Companies to Invest In

These companies largely earn their competitive advantage from intangible assets and their stocks are great choices for an investor’s watchlist.

Benjamin Slupecki

2022 Selloff Has Left the U.S. Stock Market Undervalued

Flight to safety pushes defensive sectors too high while leaving growth stocks attractively priced.

Funds That Buy Like Buffett, 2022

Our annual review of funds that own the same stocks as the Oracle of Omaha.

Investing Specialists

Our Ultimate Stock-Pickers' Top 10 Dividend-Yielding Stocks

Half of the top 10 dividend-yielding names are undervalued.

Stock Strategist

Merck's Stock Is Underappreciated

The drugmaker offers investors robust growth and an attractive dividend, notes Morningstar's analyst.

Stock Strategist Industry Reports

Will Vaccine Manufacturers' Windfalls Continue Beyond 2022?

We think the COVID-19 treatment market will have more longevity.

Pullback an Opportunity to Pick Up Undervalued Stocks

Value remains attractive, but time to rotate back into growth … and even some tech.

Investing Specialists

Weekly Wrap: Undervalued Stocks for 2022, Outlook for the Market and Economy, and Your 2022 Financial Calendars

And also Tesla.

Morningstar.com

Quarter-End Insights

Healthcare Stocks Dogged by U.S. Policy Concerns

Large biopharma names are undervalued while device and diagnostic industries look pricey.

33 Undervalued Stocks for 2022

Here are our analysts' top ideas in each sector for the new year.

Susan Dziubinski

Stock Analyst Update

Merck's COVID-19 Drug Posts Poor Data; No Change to FVE

Merck’s updated analysis for its coronavirus treatment, molnupiravir, could aid Pfizer’s COVID-19 treatment, Paxlovid.

3 Warren Buffett Stocks on Sale

These undervalued stocks are among the holdings in Berkshire Hathaway today.

Susan Dziubinski

These ESG Funds Have Style

A look at how ESG integration interacts with style biases.

Stock Strategist Industry Reports

Big Biopharma Capital Allocation Supports Undervalued Stocks and Dividend Growth

Our top two picks in this wide-moat industry are poised to benefit.

Big Biotech Shares Take a Wild Ride

As the post-pandemic pharma landscape takes shape, Moderna and BioNTech slide, Pfizer rallies.

Stock Analyst Update

Pfizer Posts Strong Data on COVID Drug Paxlovid

We don’t expect any major change to our fair value estimate or the fair values for firms with competing COVID treatments, including Merck.

Stock Analyst Update

Merck's Growth Potential Remains Underappreciated

The wide-moat company reported a strong third quarter, but we don't expect any significant changes to our fair value estimate.

10 Scary Stocks: 2021 Edition

These are the most overpriced stocks in our coverage universe today.

Susan Dziubinski

Transparency is our policy. Learn how it impacts everything we do.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.